SCHEMBL2929499

SCHEMBL2929499

O=C(O)c1conc1-c1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDH1 P12830 2/20 0.46
CTNNB1 P35222 2/20 0.46
TCF7L2 Q9NQB0 2/20 0.46
APC P25054 1/20 0.46
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
GPBAR1 Q8TDU6 1/20 0.43
FFAR4 Q5NUL3 1/20 0.42
PTPN1 P18031 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
DHODH Q02127 5/20 0.40
CSNK2A2 P19784 1/20 0.40
CSNK2B P67870 1/20 0.40
TSHR P16473 2/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6004036 0.85 GPBAR1 (0.45) CDH1CTNNB1TCF7L2APCNPC1
SCHEMBL4024790 0.84 ALDH1A1 (0.45) MEN1KMT2AL3MBTL1DHODHTSHR
SCHEMBL1225673 0.84 PTGS2 (0.44) NPC1RAB9APTPN1MEN1KMT2A
SCHEMBL402939 0.83 ALDH1A1 (0.46) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL1776666 0.83 MAPK13 (0.49) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL4022249 0.83 TPMT (0.39) CTNNB1PTPN1KMT2AKDM4EMAPK14
SCHEMBL27934992 0.82 PTGS2 (0.43) NPC1RAB9APTPN1MEN1KMT2A
SCHEMBL4025736 0.82 PTPN1 (0.37) RAB9AFFAR4PTPN1SMN1; SMN2
SCHEMBL25458022 0.81 GABRA5 (0.46) GPBAR1FFAR4PTPN1LMNA
SCHEMBL27946184 0.81 SLC6A3 (0.51) NPC1RAB9AGPBAR1PTPN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2229383-B1 ISOXAZOLO-PYRAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2017-01-18 EP disclosed
EP-2768827-B1 PROCESS FOR THE PREPARATION OF ISOXAZOLYL-METHOXY-NICOTINIC ACIDS HOFFMANN LA ROCHE (CH) 2016-11-23 EP disclosed
EP-2767536-B1 Isoxazolo-pyridine derivatives HOFFMANN LA ROCHE (CH) 2015-09-02 EP disclosed
US-9073908-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2015-07-07 US disclosed
EP-2227467-B1 ISOXAZOLO-PYRIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-12-31 EP disclosed
US-8877782-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2014-11-04 US disclosed
US-8877783-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2014-11-04 US disclosed
US-8846719-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2014-09-30 US disclosed
EP-2768827-A1 PROCESS FOR THE PREPARATION OF ISOXAZOLYL-METHOXY-NICOTINIC ACIDS F.HOFFMANN-LA ROCHE AG (CH) 2014-08-27 EP disclosed
EP-2767536-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2014-08-20 EP disclosed
US-20120184538-A1 ISOXAZOLO-PYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2012-07-19 US disclosed
US-7902201-B2 Isoxazolo-pyrazine derivatives HOFFMANN-LA ROCHE INC. (US) 2011-03-08 US disclosed
CN-101889010-A Isoxazolo-pyridine derivatives HOFFMANN LA ROCHE 2010-11-17 CN disclosed
CN-101883769-A Isoxazole-pyrazine derivatives HOFFMANN LA ROCHE 2010-11-10 CN disclosed
US-20100256154-A1 ISOXAZOLO-PYRAZINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
EP-2229383-A1 ISOXAZOLO-PYRAZINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-22 EP disclosed
EP-2227467-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-15 EP disclosed
WO-2009071476-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-11 WO disclosed
WO-2009071464-A1 ISOXAZOLO-PYRAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-11 WO disclosed
US-20090143371-A1 ISOXAZOLE-PYRIDINE DERIVATIVES ROCHE PALO ALTO LLC 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143371-A1 ISOXAZOLE-PYRIDINE DERIVATIVES GABRA5, GABRA1, CHRNA5 CDH1 4439/4885CTNNB1 2811/4885TCF7L2 1306/4885
US-20100256154-A1 ISOXAZOLO-PYRAZINE DERIVATIVES GABRA5, GRIK5, GABRA4 CDH1 4578/4885CTNNB1 2777/4885TCF7L2 813/4885
US-20120184538-A1 ISOXAZOLO-PYRIDINE DERIVATIVES GABRA5, GABRA1, GABRA4 CDH1 4402/4885CTNNB1 2587/4885TCF7L2 1029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.